Intuitive Surgical's dive continues on prostate surgery study
A study showing that surgery for prostate cancer is unnecessary sends shares of Intuitive Surgical down another 8% today.
Wall Street investors are taking another bite out of Intuitive Surgical (NSDQ:ISRG) today, sending its share price down nearly 8% on a study showing that prostate surgery is un-necessary for many men.
ISRG shares dropped fast on Wall Street yesterday afternoon, fueled by the study and soft prostatectomy procedure volumes.
Despite 26% sales growth and 32% profit growth, the stock had lost 5.7% by the end of the company's conference call, trading after-hours at $513.40 as of about 5:25 p.m. yesterday.
Shares were down another 7.7% to $502.54 as of about 1:40 p.m. today.